Patent ID: 6673778
Filing Date: 2004-01-06
Classification: A61K,C12N

Abstract:
A method of inhibiting metabolism of a drug administered to a subject, comprisingco-administering with said drug a morpholino antisense oligomer effective to reduce expression of a cytochrome p450 enzyme that catalyzes metabolism of the drug in said subject, by hybridizing to a target RNA molecule which encodes said enzyme, wherein the cytochrome p450 enzyme is selected from the group consisting of CYP2B1, CYP2E1, CYP3A2, and CYP3A4, and wherein said morpholino antisense oligomer has a base sequence selected from the group consisting of: SEQ ID NO: 16, for inhibition of CYP2B1; SEQ ID NOs: 18-20 and 23, for inhibition of CYP2E1; SEQ ID NOs: 24 and 25, for inhibition of CYP3A2; and SEQ ID NOs: 35, 46, and 47, for inhibition of CYP3A4; and is administered transdermally to the subject.